Show simple item record

dc.contributor.authorFrese, Kristopher K
dc.contributor.authorSimpson, Kathryn L
dc.contributor.authorDive, Caroline
dc.date.accessioned2021-04-06T15:06:58Z
dc.date.available2021-04-06T15:06:58Z
dc.date.issued2021en
dc.identifier.citationFrese KK, Simpson KL, Dive C. Small cell lung cancer enters the era of precision medicine. Cancer Cell. 2021;39(3):297-9.en
dc.identifier.pmid33577787en
dc.identifier.doi10.1016/j.ccell.2021.02.002en
dc.identifier.urihttp://hdl.handle.net/10541/623822
dc.description.abstractIn this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new "inflamed" subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ccell.2021.02.002en
dc.titleSmall cell lung cancer enters the era of precision medicineen
dc.typeArticleen
dc.contributor.departmentCancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester,en
dc.identifier.journalCancer Cellen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record